Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients

(2015) Duane A. Mitchell et al.   NATURE

Immune checkpoint modulation: Rational design of combination strategies

(2015) Dmitriy Zamarin et al.   PHARMACOLOGY & THERAPEUTICS

Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

(2015) Carolien A.E. Koks et al.   Journal of Cancer

Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells

(2015) Gang Meng et al.   Oncotarget

Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death

(2014) Carolien A. Koks et al.   INTERNATIONAL JOURNAL OF CANCER

Cytokine-enhanced intravenous oncolytic virotherapy

(2014) Oliver Donnelly et al.   LANCET

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity

(2013) A. Castleton et al.   BLOOD

OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients

(2013) B. D. Curti et al.   CANCER RESEARCH

Autologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function

(2013) Volker Schirrmacher et al.   Expert Review of Vaccines

The Oncolytic Activity of Newcastle Disease Virus in Clear Cell Renal Carcinoma Cells in Normoxic and Hypoxic Conditions: The Interplay Between von Hippel-Lindau and Interferon-β Signaling

(2013) Wei-Choong Ch'ng et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Prostate-Specific Antigen-Retargeted Recombinant Newcastle Disease Virus for Prostate Cancer Virotherapy

(2013) R. Shobana et al.   JOURNAL OF VIROLOGY

Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens

(2013) Leonardo Susta et al.   MICROBIAL PATHOGENESIS

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunogenic Cell Death in Cancer Therapy

(2012) Guido Kroemer et al.   Annual Review of Immunology

Velogenic Newcastle Disease Virus as an Oncolytic Virotherapeutics: In Vitro Characterization

(2012) Rajiv Kumar et al.   APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY

Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication

(2012) Chunchun Meng et al.   ARCHIVES OF VIROLOGY

Bispecific Antibodies and Trispecific Immunocytokines for Targeting the Immune System Against Cancer

(2012) Philippe Fournier et al.   BIODRUGS

Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions

(2012) Dmitriy Zamarin et al.   Future Microbiology

Construction of Recombinant Newcastle Disease Virus Italien Strain for Oncolytic Virotherapy of Tumors

(2012) Ding Wei et al.   HUMAN GENE THERAPY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Apoptin Enhances the Oncolytic Properties of Newcastle Disease Virus

(2011) Yantao Wu et al.   INTERVIROLOGY

Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy

(2011) Han Yuen Lam et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells

(2011) M. Mansour et al.   JOURNAL OF VIROLOGY

The matrix (M) protein of newcastle disease virus binds to human bax through its BH3 domain

(2011) Aidin Molouki et al.   Virology Journal

Antiviral Response Dictated by Choreographed Cascade of Transcription Factors

(2010) E. Zaslavsky et al.   JOURNAL OF IMMUNOLOGY

Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer

(2010) Kyo Young Song et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Type I Interferon-Sensitive Recombinant Newcastle Disease Virus for Oncolytic Virotherapy

(2010) S. Elankumaran et al.   JOURNAL OF VIROLOGY

Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma

(2010) G. R. Silberhumer et al.   MOLECULAR CANCER THERAPEUTICS

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus

(2010) J Puhlmann et al.   ONCOGENE

Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model

(2009) E. K. Mader et al.   CLINICAL CANCER RESEARCH

The Oncolytic Activity of Newcastle Disease Virus NDV-HUJ on Chemoresistant Primary Melanoma Cells Is Dependent on the Proapoptotic Activity of the Inhibitor of Apoptosis Protein Livin

(2009) I. Lazar et al.   JOURNAL OF VIROLOGY

Activation of Natural Killer Cells by Newcastle Disease Virus Hemagglutinin-Neuraminidase

(2009) M. Jarahian et al.   JOURNAL OF VIROLOGY

Enhancement of Oncolytic Properties of Recombinant Newcastle Disease Virus Through Antagonism of Cellular Innate Immune Responses

(2009) Dmitriy Zamarin et al.   MOLECULAR THERAPY

Engineered Newcastle Disease Virus as an Improved Oncolytic Agent Against Hepatocellular Carcinoma

(2009) Jennifer Altomonte et al.   MOLECULAR THERAPY

Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial

(2008) T. Schulze et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Efficient Cross-presentation Depends on Autophagy in Tumor Cells

(2008) Y. Li et al.   CANCER RESEARCH

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008

(2008) Philippe Fournier et al.   Expert Review of Vaccines

Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes

(2008) F Pühler et al.   GENE THERAPY